Intensity Therapeutics

A new delivery technology to treat large or many tumors with in vivo data that showed superior safety and efficacy compared to the IV route.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Norwalk, CT, USA
  • Currency USD
  • Employees 1
  • Website intensitytherapeutics.com

Company Summary

Over 570,000 US cancer patients die each year; 90% due to late stage disease. Few treatment options are successful for end stage. Intensity is a pharmaceutical firm creating new chemotherapy to treat solid tumors by direct localized injection. In a mouse model of large pancreatic tumors our approach reduced the number of live cancer cells from baseline with few side effects (IV dosing did not) and is promising for metastatic disease treatment.

Team

  • Lewis H. Bender
    President and Chief Executive Officer

    Lew Bender, SB, SM, in Chemical Engineering from MIT, MBA from UPENN’s Wharton School, and formerly CEO of Interleukin Genetics and Emisphere Technologies. At Emisphere Mr. Bender also held positions of; Chief Technology Officer, SVP of Bus. Dev., and VP of Manufacturing. He has 20 years of biotech/pharma partnering and drug development experience & led teams taking products from discovery to Phase III for drugs using novel delivery techniques

  • Dr. Jay Berzofsky
    Collaborator

    Center for Cancer Research NIH; Chief of the Molecular Immunogenetics and Cancer Vaccine Research Section

  • Lewis Bender

Advisors

  • Edwards Wildman LLC
    Lawyer
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free